Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
CH Huang, JS Ju, TH Chiu, ACC Huang… - … Journal of Cancer, 2022 - Wiley Online Library
The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) afatinib improves
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …
Afatinib treatment alone or with bevacizumab in a real-world cohort of non-small cell lung cancer patients with epidermal growth factor receptor mutation
CHS Kuo, TH Chiu, PH Tung, CH Huang, JS Ju… - Cancers, 2022 - mdpi.com
Simple Summary Previous studies of first-generation EGFR-TKI erlotinib and bevacizumab
combination have demonstrated superior treatment efficacy compared to erlotinib …
combination have demonstrated superior treatment efficacy compared to erlotinib …
First-line afatinib in patients with non-small-cell lung cancer with uncommon EGFR mutations in South Korea
MH Kim, CM Choi, SY Lee, CK Park… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Non-small cell lung cancers (NSCLCs) harboring uncommon epidermal
growth factor receptor (EGFR) mutations are heterogeneous and show variable prevalence …
growth factor receptor (EGFR) mutations are heterogeneous and show variable prevalence …
Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations
I Tanaka, M Morise, Y Kodama, A Matsui… - Lung …, 2019 - lungcancerjournal.info
Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung
cancer (NSCLC) are a heterogeneous group of genetic alterations that produce variable …
cancer (NSCLC) are a heterogeneous group of genetic alterations that produce variable …
[HTML][HTML] Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
A Passaro, A Pochesci, G Spitaleri… - Journal of Thoracic …, 2016 - ncbi.nlm.nih.gov
The development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) changed dramatically the history of non-small cell lung cancer (NSCLC) harboring …
(TKIs) changed dramatically the history of non-small cell lung cancer (NSCLC) harboring …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - The lancet …, 2015 - thelancet.com
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
[HTML][HTML] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b …
F de Marinis, KK Laktionov, A Poltoratskiy, I Egorova… - Lung Cancer, 2021 - Elsevier
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer …
K Park, JS Kim, JH Kim, YC Kim, HG Kim, EK Cho… - BMC cancer, 2021 - Springer
Background Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR
mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access …
mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access …
Clinical activity of afatinib in patients with non–small-cell lung cancer harboring uncommon EGFR mutations: a Spanish retrospective multicenter study
Introduction Uncommon epidermal growth factor receptor (EGFR) mutations (u-EGFRm) are
a heterogeneous group of molecular alterations and have also been reported as …
a heterogeneous group of molecular alterations and have also been reported as …
[PDF][PDF] Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three prospective trials of afatinib in EGFR mutation-positive …
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings
from three prospective trials of af Page 1 Activity of afatinib in uncommon epidermal growth …
from three prospective trials of af Page 1 Activity of afatinib in uncommon epidermal growth …